~~<i id='D04C197E48'><strike id='D04C197E48'><tt id='D04C197E48'><pre id='D04C197E48'></pre></tt></strike></i>~~

Home» focus» knowledge

knowledge

author：explore 2025-09-28 12:08:21 Page View：863

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional drug candidates for its pipeline of cardiometabolic medicines.

Cardior focuses on targeting RNA to address the root causes of heart disease. Its lead candidate, known CDR132L, is in Phase 2 development as a treatment for health failure.

The companies did not disclose how much Novo was paying upfront for Cardior and how much would be based on future milestones being achieved. The deal is expected to close in the second quarter.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to increase colonoscopy rates? Looks like an AI can help
Next article： Medicare proposal to cover medical devices draws a mixed reaction

comprehensive

Apple is now the first public company to be valued at $3 trillion

6:09FILE-AnApplelogoadornsthefacadeofthedowntownBrooklynApplestoreonMarch14,2020,inNewYork.Applebeca

With trial win, GSK could get blood cancer drug back on market

JUSTINTALLIS/AFPviaGettyImagesLONDON—TheresurrectionofaGSKbloodcancerdrug—whichthecompanywithdrewfro

Activists slam private health insurers over coverage restrictions

ProtestorsoutsideAmerica'sHealthInsurancePlansheadquarters.CourtesyPeople'sActionWASHINGTON—Hun

Intellia reports positive results for its CRISPR

RubyWallauforSTATIntelliaTherapeuticssaidSundaythatthefirst10patientstoreceiveaCRISPR-basedtreatment